Processa Pharmaceuticals announces 1-for-25 reverse stock split effective Dec 16, 2025

Processa Pharmaceuticals, Inc.

Reverse split reduces outstanding shares 25:1; no change to authorized shares (1B).
Effective 5:00 p.m. ET Dec 16, 2025; split-adjusted trading begins Dec 17, 2025 under symbol PCSA.
New CUSIP number 74275C403; fractional shares rounded up to nearest whole share.
Outstanding options, warrants, and RSUs adjusted proportionally per their terms.
Stockholders' ownership percentages unchanged except for fractional share rounding.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals filed a Certificate of Amendment to effect a 1-for-25 reverse stock split of common stock (effective 2025-12-16).

Change: charter amendment
Effective: 2025-12-16

Exact text from the filing

On December 12, 2025, Processa Pharmaceuticals, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Fourth Amended and Restated Certificate of Incorporation to effect a 1-for-25 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), effective as of 5:00 p.m. Eastern Time on December 16, 2025.

View on SEC.gov

268 governance changes filed in the last 30 days. Browse all governance changes →

Processa Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-027680

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.